Key result
High plasma levels of soluble CD40 ligand increased the risk of vascular events in patients with nonvalvular atrial fibrillation.
Why the study?
Does elevated soluble CD40 ligand predict stroke or myocardial infarction in patients with nonvalvular atrial fibrillation?
Cohort (n=231)
Does elevated soluble CD40 ligand predict stroke or myocardial infarction in patients with nonvalvular atrial fibrillation?
Elevated soluble CD40 ligand is a strong independent predictor of vascular events (stroke and MI) in patients with nonvalvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Elevated sCD40L was associated with higher vascular risk in nonvalvular AF; leaves open its incremental value for risk stratification.
OBJECTIVE: Atrial fibrillation (AF) is associated with a high incidence of vascular disease that may be related to a prothrombotic and inflammatory state. Soluble CD40 ligand (sCD40L), which stems essentially from platelet activation, possesses inflammatory and prothrombotic properties. The aim of the study was to assess whether sCD40L is a predictor of stroke or myocardial infarction (MI) in patients with nonvalvular AF. METHODS AND RESULTS: Plasma levels of sCD40L were measured in 231 patients (177 [77%] had permanent or persistent AF, and 54 [23%] had paroxysmal AF). Patients were followed for a mean period of 27.8+/-8.8 months, and cardiovascular events such as fatal and nonfatal stroke and MI were recorded. AF population was divided in 2 groups according to sCD40L level above or below the median (4.76 ng/mL). The 2 patients' groups had similar distribution of cardiovascular risk factors, age, gender, medications, or serum C-reactive protein levels. During the follow-up period, vascular events occurred in 6 (2 nonfatal MI and 4 nonfatal ischemic strokes) of 116 patients with low levels of sCD40L (5.1%) and in 29 (11 fatal and 3 nonfatal MI; 3 fatal and 12 nonfatal ischemic strokes) of 115 patients with high levels (25.2%) (log-rank test: P<0.001). Using the COX proportional Hazards model, patients with sCD40L above the median were 4.63 times more likely to experience a vascular event (95% C.I.: 1.92 to 11.20). CONCLUSIONS: This study shows that enhanced soluble CD40L level is a predictor of vascular events in patients with nonvalvular AF, thus suggesting that enhanced platelet activation may play a role in its clinical progression.
No takes yet. Share an insight, caveat, or question.
Ferro et al. (2007) conducted a cohort in Nonvalvular atrial fibrillation (n=231). High soluble CD40 ligand (sCD40L) levels (>4.76 ng/mL) vs. Low soluble CD40 ligand (sCD40L) levels (≤4.76 ng/mL) was evaluated on Vascular events (fatal and nonfatal stroke and myocardial infarction) (HR 4.63, 95% CI 1.92 to 11.20, p=<0.001). High plasma levels of soluble CD40 ligand increased the risk of vascular events in patients with nonvalvular atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: